These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35300206)

  • 1. The Oncogenic and Diagnostic Potential of Stanniocalcin 2 in Hepatocellular Carcinoma.
    Wu Z; Cheng H; Liu J; Zhang S; Zhang M; Liu F; Li Y; Huang Q; Jiang Y; Chen S; Lv L; Li D; Zeng JZ
    J Hepatocell Carcinoma; 2022; 9():141-155. PubMed ID: 35300206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma.
    Zhang ZH; Wu YG; Qin CK; Rong ZH; Su ZX; Xian GZ
    Oncol Lett; 2014 Nov; 8(5):2160-2164. PubMed ID: 25289096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of high expression of stanniocalcin-2 in hepatocellular carcinoma.
    Wang Y; Wu J; Xu J; Lin S
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30962272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
    World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.
    Mao L; Wang Y; Wang D; Han G; Fu S; Wang J
    PLoS One; 2017; 12(9):e0183880. PubMed ID: 28902891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro.
    Wang H; Wu K; Sun Y; Li Y; Wu M; Qiao Q; Wei Y; Han ZG; Cai B
    BMB Rep; 2012 Nov; 45(11):629-34. PubMed ID: 23187001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum biomarkers for early detection of hepatocellular carcinoma associated with HCV infection in egyptian patients.
    Zekri AR; Youssef AS; Bakr YM; Gabr RM; El-Rouby MN; Hammad I; Ahmed EA; Marzouk HA; Nabil MM; Hamed HA; Aly YH; Zachariah KS; Esmat G
    Asian Pac J Cancer Prev; 2015; 16(3):1281-7. PubMed ID: 25735368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and Prognostic Roles of Serum Osteopontin and Osteopontin Promoter Polymorphisms in Hepatitis B-related Hepatocellular Carcinoma.
    Chimparlee N; Chuaypen N; Khlaiphuengsin A; Pinjaroen N; Payungporn S; Poovorawan Y; Tangkijvanich P
    Asian Pac J Cancer Prev; 2015; 16(16):7211-7. PubMed ID: 26514514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma.
    Zhang HJ; Yao DF; Yao M; Huang H; Wu W; Yan MJ; Yan XD; Chen J
    World J Gastroenterol; 2012 Nov; 18(41):5897-904. PubMed ID: 23139605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STC2 is a potential biomarker of hepatocellular carcinoma with its expression being upregulated in Nrf1α-deficient cells, but downregulated in Nrf2-deficient cells.
    Bu Q; Deng Y; Wang Q; Deng R; Hu S; Pei Z; Zhang Y
    Int J Biol Macromol; 2023 Dec; 253(Pt 8):127575. PubMed ID: 37866563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
    Sun Y; Zhu S; Wu Z; Huang Y; Liu C; Tang S; Wei L
    Oncotarget; 2017 Apr; 8(14):23427-23435. PubMed ID: 28178643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas.
    Lin S; Guo Q; Wen J; Li C; Lin J; Cui X; Sang N; Pan J
    J Exp Clin Cancer Res; 2014 Mar; 33(1):26. PubMed ID: 24606961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma.
    Tsai JF; Jeng JE; Chuang LY; You HL; Wang LY; Hsieh MY; Chen SC; Chuang WL; Lin ZY; Yu ML; Dai CY
    Scand J Gastroenterol; 2005 Jan; 40(1):68-75. PubMed ID: 15841717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma interleukin 17 in the diagnosis of hepatocellular carcinoma: a retrospective study of 39 cases.
    Liu J; Zhou G; Lu W
    J Cancer Res Ther; 2014 Dec; 10 Suppl():304-6. PubMed ID: 25693940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of stanniocalcin-1 and stanniocalcin-2 in laryngeal squamous cell carcinoma and correlations with clinical and pathological parameters.
    Zhou H; Li YY; Zhang WQ; Lin D; Zhang WM; Dong WD
    PLoS One; 2014; 9(4):e95466. PubMed ID: 24743310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
    Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
    PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stanniocalcin 2 contributes to aggressiveness and is a prognostic marker for oral squamous cell carcinoma.
    Ferreira do Carmo A; Dourado MR; Ervolino de Oliveira C; Bastos DC; Domingueti CB; Ribeiro Paranaíba LM; Sawazaki-Calone Í; Borges GÁ; Silva Guerra EN; Casarin RC; Graner E; Salo TA; de Almeida Freitas R; Galvão HC; Coletta RD
    Exp Cell Res; 2020 Aug; 393(2):112092. PubMed ID: 32445747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STC2 as a novel mediator for Mus81-dependent proliferation and survival in hepatocellular carcinoma.
    Wu F; Li TY; Su SC; Yu JS; Zhang HL; Tan GQ; Liu JW; Wang BL
    Cancer Lett; 2017 Mar; 388():177-186. PubMed ID: 27939696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.